EIGR - Eiger BioPharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
11.31
-0.34 (-2.92%)
At close: 4:00PM EDT

11.84 +0.53 (4.69%)
After hours: 4:03PM EDT

Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close11.65
Open11.51
Bid11.27 x 1000
Ask12.70 x 800
Day's Range11.14 - 11.88
52 Week Range4.55 - 15.82
Volume282,354
Avg. Volume373,651
Market Cap283.388M
Beta (5Y Monthly)0.88
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • The Daily Biotech Pulse: Aldeyra Jumps Into COVID-19 Drug Fray, FDA Nod For Myriad's Companion Diagnostic Test
    Benzinga

    The Daily Biotech Pulse: Aldeyra Jumps Into COVID-19 Drug Fray, FDA Nod For Myriad's Companion Diagnostic Test

    Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 19) * ADC Therapeutics SA (NYSE: ADCT) (IPOed May 15) * Allogene Therapeutics Inc (NASDAQ: ALLO) * Arcturus Therapeutics Ltd (NASDAQ: ARCT) * Bio-Rad Laboratories, Inc. (NYSE: BIO) * BioXcel Therapeutics Inc (NASDAQ: BTAI) * ChemoCentryx Inc (NASDAQ: CCXI) * Evoke Pharma Inc (NASDAQ: EVOK) * I-Mab ADR (NASDAQ: IMAB) * Imara Inc (NASDAQ: IMRA) * Intellia Therapeutics Inc (NASDAQ: NTLA) * Neurocrine Biosciences, Inc. (NASDAQ: NBIX) * Syndax Pharmaceuticals Inc (NASDAQ: SNDX) * Translate Bio Inc (NASDAQ: TBIO) * Twist Bioscience Corp (NASDAQ: TWST) * United Therapeutics Corporation (NASDAQ: UTHR) * VBI Vaccines Inc (NASDAQ: VBIV) * Vermillion, Inc. (NASDAQ: VRML) * Zai Lab Ltd (NASDAQ: ZLAB) * Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL)Down In The Dumps (Biotech Stocks Hitting 52-week Lows May 19) * Lyra Therapeutics Inc (NASDAQ: LYRA) (IPOed May 1)Stocks In Focus Myriad Announces FDA Approval For Companion Diagnostic Test For Prostate Cancer Myriad Genetics, Inc. (NASDAQ: MYGN) said the FDA approved the BRACAnalysis CDx test for use as a companion diagnostic by healthcare professionals to identify men with metastatic castration-resistant prostate cancer who are eligible for treatment with Lynparza.Lynparza is a novel PARP inhibitor jointly developed and commercialized by AstraZeneca plc (NYSE: AZN) and Merck & Co., Inc. (NYSE: MRK).In pre-market trading Wednesday, Myriad shares were advancing 8.21% to $15.68.Aldeyra To Advance Two Pipeline Assets Into Clinical Trials For COVID-19 Treatment Aldeyra Therapeutics Inc (NASDAQ: ALDX) announced the planned advancement of the investigational new HSP90 inhibitor ADX-1612 to clinical testing for COVID-19, and provided an update on ADX-629, a novel investigational RASP inhibitor in development for COVID-19 and other inflammatory diseases.Aldeyra announced that ADX-1612 has demonstrated nanomolar potency similar to or greater than that of remdesivir in an in vitro model. Complementary to the nucleic acid inhibition mechanism of action of remdesivir and related antiviral compounds, ADX-1612 potentially leads to the inhibition of proteins associated with viral replication and infection, and thereby may enhance the activity of other antiviral drugs for the treatment of COVID-19. Pending FDA feedback, the company expects to file an IND the third quarter of 2020.The company said ADX-629 has completed pre-IND discussions with the Pulmonary Division of the FDA, and an IND application is expected to be submitted in June 2020.In pre-market trading, shares were up 23.70% to $4.75.Eiger's NDA For Progeria Drug Accepted For Accelerated Review Eiger Biopharmaceuticals Inc (NASDAQ: EIGR) said the FDA accepted its NDA for an accelerated review of Zokinvy for treatment of Progeria and Progeroid Laminopathies. The PDUFA action date has been fixed for Nov. 20. The company noted that the FDA is not currently planning to hold an advisory committee meeting to discuss this application.View more earnings on IBBRelated Link: These 6 Coronavirus Vaccine Candidates Are The Likeliest To Succeed, Says Morgan StanleyBio-Techne Announces Pact to Develop and Scale Up Serology Test Kits For Coronavirus BIO-TECHNE Corp (NASDAQ: TECH) and Kantaro Biosciences, the commercial affiliate of the Mount Sinai Health System in New York, announced a partnership to initiate scaled manufacturing and distribution of testing kits based on the Mount Sinai-developed COVID-19 serology test.Bio-Techne said it has partnered with Kantaro to develop a test kit based on the Mount Sinai test and to scale up, manufacture, sell and distribute these kits. Initial kit production capacity is expected to enable laboratories to conduct in excess of 10 million tests monthly in July, scaling to higher capacity in subsequent months..Offerings Ocular Therapeutix Inc (NASDAQ: OCUL) said it has commenced an underwritten public offering of its common stock. All of the shares in the offering are to be sold by the company. The company also said the offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed.The stock fell 4.65% to $6.15 in after-hours trading.Medigus Ltd. (NASDAQ: MDGS) said it has priced its underwritten public offering of 3.33 million ADSs at a price of $1.50 per ADS. Each pre-funded warrant that allows purchase of one ADS is priced at $1.499 per pre-funded warrant. The company noted that the pre-funded warrants are exercisable at any time after the date of issuance upon payment of the exercise price of $0.001 per ADS.The stock slipped 10.24% to $2.63 in after-hours trading.VolitionRX Ltd (NYSE: VNRX) said it intends to offer and sell shares of its common stock in an underwritten public offering. All the shares are being offered by the company.In after-hours trading, the stock fell 7.30% to $2.92.On The Radar Earnings Mediwound Ltd (NASDAQ: MDWD) (before the market open) China Biologic Products Holdings Inc (NASDAQ: CBPO) (after the close) Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX) (after the close)See more from Benzinga * The Daily Biotech Pulse: FDA Nod For Roche, Arbutus Releases Positive Readout For HBV Therapy, Moderna Announces .34B Common Stock Offering * The Week Ahead In Biotech: Aquestive Awaits FDA Decision, Earnings Flow Slows * The Daily Biotech Pulse: Co-Diagnostics Earnings, NantKwest Plans Pancreatic Cancer Study, ADC Therapeutics IPO(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Is Eiger BioPharmaceuticals (EIGR) Stock a Solid Choice Right Now?
    Zacks

    Is Eiger BioPharmaceuticals (EIGR) Stock a Solid Choice Right Now?

    Eiger BioPharmaceuticals (EIGR) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

  • Clinical trials in the age of COVID: Shelter-in-place, hospital restrictions cause drug study delays
    American City Business Journals

    Clinical trials in the age of COVID: Shelter-in-place, hospital restrictions cause drug study delays

    In the span of eight days last month, CytomX Therapeutics Inc. landed a collaboration with Astellas Pharma and captured a $40 million milestone payment from AbbVie Inc. as it preps for a mid-stage cancer clinical trial. “It’s a challenging time for our industry,” said CytomX President and CEO Sean McCarthy.

  • Insider Buying: The Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Founder Just Bought US$151k Worth Of Shares
    Simply Wall St.

    Insider Buying: The Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Founder Just Bought US$151k Worth Of Shares

    Potential Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) shareholders may wish to note that the Founder, Jeffrey Glenn...

  • GuruFocus.com

    Top Insider Buys Highlight for the Week of Jan. 17

    Insiders invest in JPMorgan, Simply Good Foods, Eiger BioPharmaceuticals and Geron Continue reading...

  • Trade Alert: The Chairman Of Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), Thomas Dietz, Has Just Spent US$56k Buying Shares
    Simply Wall St.

    Trade Alert: The Chairman Of Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), Thomas Dietz, Has Just Spent US$56k Buying Shares

    Whilst it may not be a huge deal, we thought it was good to see that the Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR...

  • Hedge Funds Have Never Been This Bullish On Eiger BioPharmaceuticals, Inc. (EIGR)
    Insider Monkey

    Hedge Funds Have Never Been This Bullish On Eiger BioPharmaceuticals, Inc. (EIGR)

    Looking for stocks with high upside potential? Just follow the big players within the hedge fund industry. Why should you do so? Let’s take a brief look at what statistics have to say about hedge funds’ stock picking abilities to illustrate. The Standard and Poor’s 500 Index returned approximately 26% in 2019 (through November 22nd). Conversely, hedge […]

  • Is Eiger BioPharmaceuticals, Inc. (EIGR) A Good Stock To Buy?
    Insider Monkey

    Is Eiger BioPharmaceuticals, Inc. (EIGR) A Good Stock To Buy?

    With the first-quarter round of 13F filings behind us it is time to take a look at the stocks in which some of the best money managers in the world preferred to invest or sell heading into the second quarter. One of these stocks was Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR). Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) has seen […]

  • Do Institutions Own Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Shares?
    Simply Wall St.

    Do Institutions Own Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Shares?

    If you want to know who really controls Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), then you'll have to look at the...

  • Need To Know: Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Insiders Have Been Buying Shares
    Simply Wall St.

    Need To Know: Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Insiders Have Been Buying Shares

    We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are...

  • What Makes Eiger BioPharma (EIGR) a New Buy Stock
    Zacks

    What Makes Eiger BioPharma (EIGR) a New Buy Stock

    Eiger BioPharma (EIGR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).

  • Benzinga

    The Daily Biotech Pulse: PhaseBio Pumped Up, Eiger Exults On Breakthrough Therapy Designation, Biohaven Slips On Stock Sale

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 17) ArQule, Inc. (NASDAQ: ARQL )( reported positive results ...